Myeloma clinical trials at UCSF

1 research study open to eligible people

Myeloma affects plasma cells, a type of white blood cell in the bone marrow. UCSF is conducting studies on a new inhibitor drug for patients who do not respond to normal treatments. They are investigating how safe this drug is for use.

Showing trials for

  • MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

    open to eligible people ages 18 years and up

    A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).

    San Francisco 5391959, California 5332921 and other locations

Our lead scientists for Myeloma research studies include .

Last updated: